Brian Daniel Webster Sells 15,000 Shares of Kestra Medical Technologies (NASDAQ:KMTS) Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Brian Daniel Webster sold 15,000 shares of the stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $26.59, for a total transaction of $398,850.00. Following the completion of the sale, the insider directly owned 409,786 shares of the company’s stock, valued at approximately $10,896,209.74. This trade represents a 3.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Kestra Medical Technologies Trading Down 1.7%

Shares of KMTS stock traded down $0.45 during trading on Wednesday, hitting $26.52. 489,936 shares of the stock traded hands, compared to its average volume of 289,819. Kestra Medical Technologies, Ltd. has a 52-week low of $13.25 and a 52-week high of $30.00. The firm has a market capitalization of $1.55 billion and a P/E ratio of -8.37. The firm’s fifty day moving average price is $26.29 and its 200-day moving average price is $21.37. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.47 and a quick ratio of 5.47.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Kestra Medical Technologies in a research note on Wednesday, December 24th. Stifel Nicolaus set a $30.00 target price on Kestra Medical Technologies in a research report on Friday, December 12th. The Goldman Sachs Group boosted their target price on Kestra Medical Technologies from $22.00 to $25.00 and gave the company a “neutral” rating in a report on Saturday, December 13th. BTIG Research initiated coverage on Kestra Medical Technologies in a research note on Tuesday, November 18th. They set a “buy” rating and a $32.00 target price for the company. Finally, Wells Fargo & Company upped their target price on shares of Kestra Medical Technologies from $27.00 to $28.00 and gave the stock an “overweight” rating in a research report on Friday, December 12th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $29.14.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KMTS. Quarry LP acquired a new stake in shares of Kestra Medical Technologies during the 1st quarter worth about $33,000. China Universal Asset Management Co. Ltd. acquired a new stake in Kestra Medical Technologies during the third quarter worth approximately $48,000. BNP Paribas Financial Markets grew its stake in Kestra Medical Technologies by 148.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after acquiring an additional 1,638 shares during the period. Brown Brothers Harriman & Co. raised its holdings in Kestra Medical Technologies by 26.8% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after acquiring an additional 656 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey purchased a new stake in Kestra Medical Technologies in the 2nd quarter valued at about $54,000.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.